XERS (Xeris Pharma) מכפיל P/S עתידי

Complex pharmaceutical logistics and insurer pressure on margins within a narrow product portfolio create volatility for Xeris Biopharma (XERS). The forward revenue multiple visualizes these market expectations, where 8.20 represents the current metric. Meanwhile, geopolitical threats and trade conflicts have virtually no impact on the business, as production is localized in stable markets.

Revenue growth from Gvoke and Recorlev sales drives the market value of Xeris Biopharma (XERS). The company's modeled P/S ratio compares the current quote with projected sales volume, measuring the premium the market is willing to pay for future revenue streams. The price action of the company's modeled P/S reveals price deviations from fundamental expectations regarding XeriSol licensing. High indicator values signal overvaluation and risks of a capital correction.